[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"respiratory-syncytial-virus-infection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:respiratory-syncytial-virus-infection":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,42,67,99,130,162],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100578945","phase-2-remdesivir-for-the-treatment-of-upper-respiratory-tract-infection-due-to-rsv-in-immunocompromised-individuals-100578945",false,"NCT06817889","Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals","An Open-Label Study to Assess the Safety and Efficacy of Remdesivir for Treatment of Symptomatic Laboratory-Confirmed Respiratory Syncytial Virus Infection of the Upper Respiratory Tract in Patients Receiving Cellular or Bispecific Antibody Therapies","Inclusion Criteria:\n\n* Aged ≥ 18 years\n* Willing and able to provide written informed consent, or with a legal representative who can provide informed consent (where locally approved)\n* RSV confirmed by local lab testing via nucleic acid amplification test (e.g. polymerase chain reaction \\[PCR\\] or respiratory viral panel \\[RVP\\]) using an upper respiratory tract sample collected within the 5 days prior to day 1 (RDV dosing)\n* Symptomatic RSV infection of the upper respiratory tract, with symptom onset and positive microbiologic testing within the 5 days prior to day 1 (RDV dosing). Symptomatic RSV infection is defined as having new upper respiratory symptom(s) or worsening of a pre-existing upper respiratory symptom (if chronic and associated with a previously existing diagnosis, such as chronic lung disease, chronic rhinorrhea, or seasonal allergies)\n* Receiving treatment for a refractory or relapsed hematologic malignancy, or received a hematopoietic cell transplant (HCT), chimeric antigen receptor T cell therapy (CARTx), or bispecific antibody (bsAb) therapy within the past 365 days (relative to RSV diagnosis date)\n* Categorized as moderate-risk (overall score 3-6) or high-risk (overall score 7-10) per an adapted version of the Immunodeficiency Scoring Index (ISI) for RSV, as below, relative to the day of RSV diagnosis:\n\n  * 1 point:\n\n    * Recent (within the prior 30 days) allogeneic HCT, autologous HCT, or CARTx\n    * Corticosteroids within the prior 30 days for management of graft versus host disease (GVHD) or cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS).\n  * 2 points:\n\n    * Age ≥ 40 years\n  * 3 points:\n\n    * Absolute neutrophil count (ANC) \\\u003C 500 cells\u002FμL within the prior 7 days\n    * Absolute lymphocyte count (ALC) \\\u003C 200 cells\u002FµL within the prior 7 days\n* Oxygen saturation (SpO2) 93% or greater on room air and at rest (to be measured after participant has rested in a quiet room for ≥ 2 minutes, with oxygen \\[O2\\] saturation probe on finger or earlobe for ≥ 1 minute, with saturation reading remaining ≥ 93%) at screening\n* Willingness to take study drug and complete necessary study procedures\n* Participants of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception as described\n\nExclusion Criteria:\n\n* Received or receiving an approved or authorized direct-acting antiviral therapy with potential efficacy against RSV (e.g. ribavirin) for ≥ 24 hours within the prior 7 days, and\u002For expected to receive anti-RSV direct-acting antiviral therapies for RSV during the course of the study at the time of screening\n* Received or receiving investigational direct-acting antiviral therapies against RSV for the current RSV episode\n* Received any investigational anti-RSV monoclonal antibodies or off-label use of approved anti-RSV monoclonal antibodies within \\\u003C 4 months or \\\u003C 5 half-lives, whichever is longer, before screening, or expected to receive anti-RSV monoclonal antibodies during the course of the study at the time of screening\n* Received an RSV vaccine after cellular therapy or after starting the current antitumor therapeutic regimen\n* Participation in any other concurrent clinical trial of an experimental treatment for RSV, including RSV vaccines\n* Alanine aminotransferase (ALT) ≥ 5 times the upper limit of normal within 7 days prior to screening\n* Unable to tolerate nasal sampling required for this study, as determined by the investigator (e.g., history of significant epistaxis, nasopharyngeal anatomical abnormalities, nasal or sinus surgery)\n* A life expectancy of three months or less, as determined by the investigator\n* Pregnant, as determined by a Point-of-Care urine pregnancy test or reported by the patient or their electronic health record within 7 days of screening\n* Receiving, requiring, or expected to require supplemental oxygen for RSV-related illness or SpO2 \\\u003C 93% at rest \\\u003C 24 hours prior to study drug administration\n* Previous infection or treatment for RSV, or previous treatment or hospitalization for another respiratory viral infection, \\\u003C 28 days before screening\n* Documented positive test for other respiratory viruses concomitantly (limited to influenza, parainfluenza, adenovirus, human metapneumovirus, or coronavirus \\[including SARS-CoV-2\\]) ≤ 7 days prior to screening, as determined by local testing (additional testing not required)\n* Clinically significant bacteremia or fungemia ≤ 7 days prior to screening and not adequately treated, as determined by the investigator\n* Clinically significant bacterial, fungal, or viral pneumonia within two (2) weeks prior to screening and not adequately treated, as determined by the investigator\n* Clinically significant symptoms of CRS or ICANS within the prior 72 hours before screening that is not adequately controlled, as determined by the investigator\n* Any inability to take study drug or comply with study procedures that, in the opinion of the investigator, would make the participant unsuitable for the study\n* Known hypersensitivity or allergy to the study drug, its metabolites, or formulation excipients","ALL","18 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This phase II trial tests how well remdesivir works for treatment of respiratory syncytial virus (RSV) infection of the upper respiratory tract in patients receiving cellular or bispecific antibody therapy. Cellular or bispecific antibody therapies cause suppression of the immune system, making infections more frequent and reducing the body's ability to fight the infections. RSV infections are one of the most common respiratory infections in immunocompromised individuals and can cause significant pneumonia and even death. Remdesivir is in a class of medications called antivirals. It works by stopping viruses from spreading in the body.",[26,27,28],"Hematopoietic and Lymphatic System Neoplasm","Autoimmune Disease","Respiratory Syncytial Virus Infection","RECRUITING","2026-06-01",{"date":32,"type":33},"2026-06-03","ACTUAL",{"date":35,"type":33},"2025-12-23",{"date":37,"type":20},"2027-11-30",{"name":39,"class":40},"Fred Hutchinson Cancer Center","OTHER",3,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":66},"100623890","phase-3-a-phase-iii-study-of-deuremidevir-hydrobromide-for-the-treatment-of-rsv-infection-in-infants-and-young-children-100623890","NCT07402512","A Phase III Study of Deuremidevir Hydrobromide for the Treatment of RSV Infection in Infants and Young Children","A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Deurremidevir Hydrobromide for Oral Suspension in Infants and Young Children With Respiratory Syncytial Virus Infection","Inclusion Criteria:\n\n1. Infants and young children aged ≥ 1 month and ≤ 36 months, regardless of gender;\n2. Weight ≥ 2.5 kg and ≤ 20 kg;\n3. Positive RSV antigen or nucleic acid test\n4. Duration of illness due to RSV infection ≤ 96 hours;\n5. Presence of tachypnea and wheezing;\n6. Wang Bronchiolitis Score≥ 5;\n7. For subjects aged \\\u003C 12 months, head circumference should be within the normal range corresponding to their age and gender.\n\nExclusion Criteria:\n\n1. Subjects who have received protocol-specified prohibited medications:\n2. Subjects with severe intrapulmonary complications or extrapulmonary complications;\n3. Subjects requiring vasopressors or inotropic agents;\n4. Subjects with known concurrent SARS-CoV-2 infection, influenza virus infection, Mycoplasma infection, or suspected concurrent bacterial or other pathogen infections;\n5. Subjects with a known history of hypercapnia;\n6. Subjects with chronic or persistent feeding difficulties;\n7. Subjects with gastrointestinal diseases that the investigator believes may significantly affect the absorption of the study drug;\n8. Subjects with congenital metabolic abnormalities;\n9. Subjects with bronchopulmonary dysplasia requiring assisted ventilation or clinically significant congenital respiratory tract abnormalities;\n10. Subjects with congenital heart disease (CHD) that the investigator assesses may affect efficacy evaluation;\n11. Subjects with clinical evidence of hepatic decompensation; or abnormal liver function tests;\n12. Subjects with renal failure, including renal abnormalities potentially related to renal insufficiency or abnormal renal function tests;\n13. Subjects with a known history of HIV positivity, or suspected to be HIV positive by the investigator;\n14. Subjects with known or suspected primary immunodeficiency diseases or transplant recipients;\n15. Subjects with a history of epilepsy or febrile convulsions;\n16. Subjects with a personal or family history of severe allergies or allergies;\n17. Subjects with active or uncontrolled respiratory, cardiac, hepatic, central nervous system, or renal diseases, or other medical conditions deemed unsuitable for enrollment by the investigator;\n18. Subjects who participated in other drug or medical device clinical trials and received investigational products or devices;\n19. Subjects deemed unsuitable for participation in this study by the investigator for any other reason.","1 Month","36 Months",{"count":52,"type":20},498,[54],"PHASE3","This is a randomized, double-blind, placebo-controlled, parallel-group trial conducted in infants and young children aged 1 to 36 months with RSV infection.\n\nA total of 498 subjects are expected to be enrolled and randomly assigned to the investigational product group or the placebo group in a 2:1 ratio; Administration will be based on the subject's weight, with a dose of 20 mg\u002Fkg three times daily for 5 consecutive days (15 doses).",[28],"2026-03-29",{"date":59,"type":33},"2026-04-02",{"date":61,"type":33},"2026-03-11",{"date":63,"type":20},"2027-06-30",{"name":65,"class":40},"Simcere Pharmaceutical Co., Ltd",4,{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":78,"conditions":79,"keywords":82,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":4},"100631802","risk-factors-and-severity-of-bronchiolitis-in-hospitalized-children-at-assiut-university-hospital-100631802","NCT07505420","Risk Factors and Severity of Bronchiolitis in Hospitalized Children at Assiut University Hospital","Clinical Epidemiology, Risk Factors Associated With Severity and Disease Burden of Bronchiolitis in Hospitalized Children in Assiut University Hospital","Inclusion Criteria:\n\n* Children aged 1-24 months presenting with acute bronchiolitis, defined per AAP 2014 criteria: preceding upper respiratory infection, wheezing, tachypnoea (\\>60 breaths\u002Fmin \\\u003C2 months, \\>50 \\\u003C12 months, \\>40 \\>12 months), and signs of respiratory distress (nasal flaring, grunting, retractions).\n* Confirmed clinical diagnosis by a pediatric pulmonologist.\n\nExclusion Criteria:\n\n* Known congenital heart disease, chronic lung disease (e.g., bronchopulmonary dysplasia), immunodeficiency, or neuromuscular disorders.\n* Recurrent wheezing suggesting asthma.\n* Gestational age \\\u003C32 weeks without recovery or birth weight \\\u003C1500g without catch-up growth.\n* Immunosuppression, recent (within 2 weeks) systemic steroids or antibiotics.","24 Months",{"count":76,"type":20},65,"OBSERVATIONAL","The purpose of this observational study is to identify the risk factors that make bronchiolitis more severe in infants and toddlers. Bronchiolitis is a common viral lung infection that causes inflammation and airway obstruction, often leading to breathing difficulties and hospitalization in young children.\n\nResearchers will observe approximately 65 children, aged 1 to 24 months, who are admitted to Assiut University Hospital for acute bronchiolitis. Because this is an observational study, participants will receive standard medical care, and no experimental treatments will be tested.\n\nDuring the hospital stay, researchers will collect information through parent questionnaires and standard medical records. The research team will gather data on:\n\n* Family, social, and environmental factors, such as infant feeding practices, premature birth, and exposure to passive smoking.\n* The child's clinical symptoms and overall severity of illness upon arrival at the hospital.\n* Routine test results and the types of supportive care the child needs, such as extra oxygen or feeding assistance.\n* The total length of the hospital stay and whether the child requires intensive care (ICU) admission.\n\nBy identifying which factors are most closely linked to severe illness, the study aims to help doctors better predict the course of the disease early on, evaluate adherence to treatment guidelines, and ultimately reduce the health burden of bronchiolitis.",[80,81,28],"Bronchiolitis","Acute Bronchiolitis",[80,81,83,84,85,86,87,88],"Respiratory Syncytial Virus Infections","Lower Respiratory Tract Infection","Respiratory Tract Infections","Viral Respiratory Infection","Wheezing","Respiratory Distress","NOT_YET_RECRUITING","2026-03-26",{"date":92,"type":33},"2026-04-01",{"date":94,"type":20},"2026-05",{"date":96,"type":20},"2027-06",{"name":98,"class":40},"Assiut University",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":74,"enrollmentInfo":107,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":109,"conditions":110,"keywords":112,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":125,"leadSponsor":127,"locationsCount":129},"100625055","gut-microbiome-and-immune-response-in-severe-rsv-infection-in-vietnamese-infants-100625055","NCT07417657","Gut Microbiome and Immune Response in Severe RSV Infection in Vietnamese Infants","Impact of the Gut Microbiome on Immune Response and Disease Severity in Acute Respiratory Syncytial Virus (RSV) Infection in Vietnamese Children: A Prospective Observational Study","GUT-LUNG RSV","Inclusion Criteria:\n\nAge 1 to 24 months RT-PCR positive for RSV from respiratory specimen Symptoms consistent with acute lower respiratory tract infection Parent\u002Flegal guardian provides informed consent\n\nExclusion Criteria:\n\nPrematurity \\\u003C32 weeks gestation or birthweight \\\u003C1500 g Chronic conditions (e.g., congenital heart disease, chronic lung disease, chronic liver\u002Fkidney disease) Primary or acquired immunodeficiency Severe malnutrition (weight-for-age Z-score \\\u003C -3 SD) Antibiotic use within 2 weeks before admission Probiotic use within 4 weeks before admission Co-infection with other pathogens (viral\u002Fbacterial) Stool sample not obtained within 24 hours of admission",{"count":108,"type":20},250,"Respiratory syncytial virus (RSV) is a leading cause of severe lower respiratory tract infection in young children, and a substantial proportion of severe cases occur in previously healthy infants. The gut-lung axis suggests that gut microbiome composition may modulate respiratory immune responses. This prospective observational study in Vietnam will compare gut microbiome profiles and systemic immune cytokine responses between infants with severe RSV infection and those with mild RSV infection, aiming to identify microbiome-immune signatures associated with disease severity.",[28,80,111],"Viral Lower Respiratory Tract Infection (LRTI)",[113,114,115,116,117,118,119,80,120],"RSV","gut microbiome","16S rRNA","Gut-lung axis","Vietnam","infants","Biomarkers","Lower respiratory tract infection","2026-02-11",{"date":123,"type":33},"2026-02-18",{"date":92,"type":20},{"date":126,"type":20},"2029-12-31",{"name":128,"class":40},"Phuc Huu Phan",1,{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":16,"minAge":138,"maxAge":139,"enrollmentInfo":140,"targetDuration":142,"studyType":77,"phases":4,"briefSummary":143,"conditions":144,"keywords":148,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":4},"100619618","rsv-positive-children-5-years-presenting-to-pediatric-emergency-departments-in-trkiye-trust-rsv-100619618","NCT07346963","RSV-Positive Children \u003C5 Years Presenting to Pediatric Emergency Departments in Türkiye: TRUST-RSV","Evaluation of Demographic, Clinical, and Healthcare Utilization Characteristics of Respiratory Syncytial Virus (RSV) Positive Cases Under 5 Years Presenting to Pediatric Emergency Departments in Türkiye: A Multicenter, Prospective Observational Study (TRUST-RSV)","TRUST-RSV","Inclusion Criteria:\n\n* Age \\\u003C5 years at presentation\n* Presentation during RSV season (2025-2026 )\n* RSV infection confirmed from a nasopharyngeal sample by rapid antigen test or PCR according to site capacity\n* Presentation to a participating pediatric ED with at least one of the following clinical diagnoses: upper respiratory tract infection, bronchiolitis, pneumonia, apnea, seizure\u002Fconvulsion, or myocarditis\n* Written informed consent obtained from a parent or legal guardian.\n\nExclusion Criteria:\n\n* Parent or legal guardian declines consent","28 Days","5 Years",{"count":141,"type":20},4000,"30 Days","Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory tract infection in infants and young children and contributes substantially to pediatric emergency department (ED) visits and hospitalizations. In Türkiye, nationally representative prospective data describing the epidemiology, clinical spectrum, and resource utilization of RSV-positive children presenting to pediatric EDs remain limited. This multicenter prospective observational study aims to characterize demographic and clinical features of RSV-positive children under 5 years of age presenting to participating pediatric EDs across two consecutive RSV seasons, and to quantify key healthcare utilization outcomes, including ED observation duration, hospitalization, and intensive care unit (ICU) admission.",[28,145,146,147],"Acute Bronchiolitis Due to Respiratory Syncytial Virus","Pneumonia","Upper Respiratory Tract Infection",[149,150,151,152],"pediatric emergency department","multicenter","prospective","healthcare utilization","2026-01-08",{"date":155,"type":33},"2026-01-16",{"date":157,"type":20},"2026-01-01",{"date":159,"type":20},"2027-06-01",{"name":161,"class":40},"Eskisehir Osmangazi University",{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":168,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":16,"minAge":170,"maxAge":4,"enrollmentInfo":171,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":173,"conditions":174,"keywords":175,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":129},"100611361","genotype-and-disease-burden-of-rsv-in-older-vietnamese-adults-rsv-respiratory-syncytial-virus--100611361","NCT07239583","Genotype and Disease Burden of RSV in Older Vietnamese Adults (RSV: Respiratory Syncytial Virus )","A Description of the Proportion, Genotype Distribution of Respiratory Syncytial Virus and the Severity of Disease in Hospitalized Elderly in Vietnam","RSV-VN-Elderly","Inclusion Criteria:\n\nTo be enrolled in the study, participants must meet all inclusion criteria:\n\n1. Individuals ≥ 60 years old at the time of screening (calculated from the date of birth to the date of screening)\n2. ARI or exacerbation of cardiopulmonary diseases diagnosed at the time of admission. ARI or ARI-compatible symptoms were defined as either:\n\n   * New onset or increase from baseline of: nasal congestion, rhinorrhea, sore throat, hoarseness, cough, sputum production, dyspnea, wheezing, hypoxemia, or\n   * Admitting diagnosis suggestive of ARI (e.g., pneumonia, upper respiratory infection, bronchitis, influenza, cough, viral respiratory illness, respiratory distress, or respiratory failure), or\n   * Admitting diagnosis was the exacerbation of an underlying cardiac or pulmonary disease involving acute respiratory symptoms within the previous 2 weeks (e.g., congestive heart failure \\[CHF\\], chronic obstructive pulmonary disease \\[COPD\\], or asthma exacerbation).\n3. The participant agrees to voluntarily participate in this study.\n\nExclusion Criteria:\n\nTo be enrolled in the study, participants must have none of the exclusion criteria:\n\n1. Symptom onset \\> 6 days prior to screening date\n2. Acute symptoms confirmed to be unrelated to infection or as assessed by the investigator\n3. Admission to any hospital within the 30 days preceding the screening date\n4. Previously enrolled in the study in the last 45 days","60 Years",{"count":172,"type":20},1000,"This observational, prospective, multicenter study aims to estimate the proportion of RSV infection in adults aged 60 years and older hospitalized due to acute respiratory infections or exacerbation of cardiopulmonary disease.",[28,83],[176,177,178,179,180,181],"Respiratory Syncytial Virus (RSV)","Acute Respiratory Infection (ARI)","Metagenomic Sequencing (mNGS)","RSV Genotype","Disease Severity","Healthcare Resource Utilization","2025-11-16",{"date":184,"type":33},"2025-11-20",{"date":186,"type":33},"2025-10-06",{"date":188,"type":20},"2027-03-30",{"name":190,"class":40},"Tam Anh Research Institute"]